# HS research update (2026-10-15): What’s new on PubMed?

Canonical URL: https://www.acneinversa.life/en/blog/hs-research-update-2026-10-15/
Markdown URL: https://www.acneinversa.life/en/blog/hs-research-update-2026-10-15.md
Plain text URL: https://www.acneinversa.life/en/blog/hs-research-update-2026-10-15.txt
Language: en
Category: Research
Published: 2026-10-15
Last updated: 2026-10-15
Last editorially reviewed: 2026-10-15
Next scheduled review: 2027-10-15

Author: Dr. rer. nat. Dennis Alexander Kwiatkowski (Biochemist, Scientific Writer and Pharma Expert)
Scientific editor: Dr. rer. nat. Dennis Alexander Kwiatkowski
Reviewer qualifications: Biochemist, Scientific Writer and Pharma Expert
Review scope: Scientific literature, clinical guidelines, sources, and editorial clarity
Clinical reviewer: No independent clinical review
Tags: Acne Inversa, Hidradenitis Suppurativa, HS, Research, hidradenitis suppurativa, acne inversa, research update, biologics, comorbidities, jak inhibitor, pain, quality of life, surgery, wound care

> A patient-friendly overview of new PubMed publications on hidradenitis suppurativa (acne inversa) — with sources, clear limitations, and no medical advice.

Medical disclaimer: This website is for general educational information only and does not replace medical advice, diagnosis, or treatment. Please speak with qualified medical professionals about symptoms or treatment decisions.

## Article

## Publication overview

This update includes **18 PubMed publications with abstracts** from the monitoring window **2026-10-01 to 2026-10-15**. The most common themes are **biologics, comorbidities, surgery, wound care, quality of life**.

- Compared with the previous update: not automatically assessed.
- This is a research overview, not a guideline update or medical recommendation.

## Top highlights

The most useful signal this round is not a single treatment instruction. It is what researchers are looking at more closely: wound healing after procedures, possible new anti-inflammatory approaches, care quality, and comorbidities. These are early research directions, and findings from individual studies may not apply to every patient or translate into changes in care.

- **Optimizing therapy in hidradenitis suppurativa: Combination, sequencing and treat-to-target.:** The abstract describes a new publication. In practical terms, it focuses on this question or finding: Hidradenitis suppurativa (HS) is a chronic, recurrent and progressively destructive inflammatory disease associated with substantial physical, psychological and social burden. The therapeutic landscape of HS has rapid… What makes it notable here is that it approaches HS through **surgery, biologics, pain, comorbidities, quality of life**. The main limitation to keep in mind is: From the abstract alone, it is hard to judge the study design, patient selection, and follow-up in full. ([PMID 42865135](https://pubmed.ncbi.nlm.nih.gov/42865135/))
- **Treatment Sequencing With Biologic Switching, Staged Excision, and Split-Thickness Skin Grafting for Extensive Hidradenitis Suppurativa.:** The abstract describes a new publication. In practical terms, it focuses on this question or finding: Treatment of extensive multiregional hidradenitis suppurativa requires sequencing biologic therapy and surgery when active inflammation and irreversible structural disease coexist. A 58-year-old Japanese man with Hurl… What makes it notable here is that it approaches HS through **pain, surgery, biologics, wound care**. The main limitation to keep in mind is: From the abstract alone, it is hard to judge the study design, patient selection, and follow-up in full. ([PMID 42875379](https://pubmed.ncbi.nlm.nih.gov/42875379/))
- **The Metabolic-Dermatologic Axis: GLP-1/GIP Agonists as Emerging Immunometabolic Therapies for Obesity-Associated Skin Disease.:** The abstract describes a new publication. In practical terms, it focuses on this question or finding: Obesity is increasingly recognized as a systemic determinant of dermatologic disease rather than merely a comorbidity accompanying skin disorders. Excess adiposity promotes insulin resistance, adipose-tissue dysfuncti… What makes it notable here is that it approaches HS through **biologics, comorbidities, wound care**. The main limitation to keep in mind is: From the abstract alone, it is hard to judge the study design, patient selection, and follow-up in full. ([PMID 42863769](https://pubmed.ncbi.nlm.nih.gov/42863769/))
- **Sonelokimab, a novel IL-17A- and IL-17F-inhibiting nanobody for the treatment of moderate-to-severe hidradenitis suppurativa: a global, randomized, double-blind, placebo-controlled phase 2 clinical trial (MIRA).:** The abstract describes a clinical trial. In practical terms, it focuses on this question or finding: Hidradenitis suppurativa (HS) is a chronic disabling and debilitating inflammatory disease with limited therapeutic options. OBJECTIVE: To present the primary results of the phase 2 MIRA trial, which evaluated the eff… What makes it notable here is that it approaches HS through **biologics**. The main limitation to keep in mind is: From the abstract alone, it is hard to judge the study design, patient selection, and follow-up in full. ([PMID 42822776](https://pubmed.ncbi.nlm.nih.gov/42822776/))
- **The overlooked surface: cutaneous manifestations of inflammatory bowel disease.:** The abstract describes a new publication. In practical terms, it focuses on this question or finding: Inflammatory bowel disease (IBD) is characterized by a chronic, idiopathic inflammation of the intestinal tract. The primary types include ulcerative colitis (UC), which affects the colon and rectum with continuous mu… What makes it notable here is that it approaches HS through **biologics, comorbidities**. The main limitation to keep in mind is: From the abstract alone, it is hard to judge the study design, patient selection, and follow-up in full. ([PMID 42866820](https://pubmed.ncbi.nlm.nih.gov/42866820/))

## Featured publication

The featured paper is **Sonelokimab, a novel IL-17A- and IL-17F-inhibiting nanobody for the treatment of moderate-to-severe hidradenitis suppurativa: a global, randomized, double-blind, placebo-controlled phase 2 clinical trial (MIRA).** in **Journal of the American Academy of Dermatology** ([PMID 42822776](https://pubmed.ncbi.nlm.nih.gov/42822776/)). The abstract mainly says this: Hidradenitis suppurativa (HS) is a chronic disabling and debilitating inflammatory disease with limited therapeutic options. OBJECTIVE: To present the primary results of the phase 2 MIRA trial, which evaluated the eff…

Why it stands out: it connects to the priority theme **biologics** and shows what HS researchers are trying to clarify right now. Highlighting a study here is not an endorsement of any specific medicine or treatment approach. For readers, it matters because it gives one concrete example of how the field is framing a practical question or possible mechanism. The main limitation is that From the abstract alone, it is hard to judge the study design, patient selection, and follow-up in full.

## What this may mean for patients (carefully, no advice)

If you live with HS, research updates can help you make sense of what’s being studied — for example which outcomes (pain, quality of life) researchers measure, or which comorbidities are increasingly part of the conversation.

But even when a study sounds promising, it usually does not tell you what is right **for you personally**. Consider using new findings as questions for your next appointment (e.g., “What are realistic goals for me?” or “Which related conditions should we keep an eye on?”), not as instructions.

## What we don’t know / limitations

- This update includes **only** PubMed items with an abstract (without an abstract, safe summarization is limited).
- Studies vary widely (design, populations, outcome measures).
- This update provides **no** treatment advice and cannot assess individual risk.

## Important: decisions belong in clinician conversations

This article is an editorial overview and is **not medically reviewed**. If something here worries or interests you, use it as a conversation starter for your next appointment. Decisions should always be made with qualified healthcare professionals.

## FAQ

### Why are there only a few new publications here?
This format is deliberately strict: it includes only new PubMed items from the monitoring window that have an abstract and were not already covered in earlier posts.

### Does a new paper mean my treatment should change?
No. A single publication can be useful to know about, but it is usually not enough to guide decisions for one specific person.

### Why emphasize limitations so much?
Because abstracts show only part of the picture. Study design, patient population, endpoints, and follow-up all matter before results can be interpreted responsibly.

## Sources & original papers

Each point below maps to an original source (PubMed link, plus DOI/PMCID when available). This article does not provide medical advice, and inclusion of a study does not imply any recommendation. Discuss any treatment questions with a qualified healthcare professional.

## References

1. Psychosocial adjustment to stigma among young adults with chronic visible skin disease. - British journal of health psychology, 2026 — PMID 42820641 · DOI 10.1111/bjhp.70110 - https://pubmed.ncbi.nlm.nih.gov/42820641/
2. Treatment Sequencing With Biologic Switching, Staged Excision, and Split-Thickness Skin Grafting for Extensive Hidradenitis Suppurativa. - The Journal of dermatology, 2026 — PMID 42875379 · DOI 10.1111/1346-8138.70538 - https://pubmed.ncbi.nlm.nih.gov/42875379/
3. Editor's Highlights-December 2026. - International journal of dermatology, 2026 — PMID 42870695 · DOI 10.1111/ijd.70739 - https://pubmed.ncbi.nlm.nih.gov/42870695/
4. Targeting an IL-17/IL-36 pathogenic hub in hidradenitis suppurativa with a bispecific antibody. - Signal transduction and targeted therapy, 2026 — PMID 42869887 · DOI 10.1038/s41392-026-02886-z - https://pubmed.ncbi.nlm.nih.gov/42869887/
5. Optimizing therapy in hidradenitis suppurativa: Combination, sequencing and treat-to-target. - Journal of the European Academy of Dermatology and Venereology : JEADV, 2026 — PMID 42865135 · DOI 10.1111/jdv.70787 - https://pubmed.ncbi.nlm.nih.gov/42865135/
6. The Metabolic-Dermatologic Axis: GLP-1/GIP Agonists as Emerging Immunometabolic Therapies for Obesity-Associated Skin Disease. - Clinics in dermatology, 2026 — PMID 42863769 · DOI 10.1016/j.clindermatol.2026.09.040 - https://pubmed.ncbi.nlm.nih.gov/42863769/
7. The future management of HS: People with HS as partners. - Journal of the European Academy of Dermatology and Venereology : JEADV, 2026 — PMID 42857969 · DOI 10.1111/jdv.70788 - https://pubmed.ncbi.nlm.nih.gov/42857969/
8. Skin and Brain in Bipolar Disorder: A Review of Dermatologic-Psychotropic Drug Interactions. - The primary care companion for CNS disorders, 2026 — PMID 42849015 · DOI 10.4088/PCC.26nr04252 - https://pubmed.ncbi.nlm.nih.gov/42849015/
9. Impact of Biologic Therapy on Emergency Department Utilization in Pediatric Hidradenitis Suppurativa Patients. - Pediatric dermatology, 2026 — PMID 42845185 · DOI 10.1111/pde.70364 - https://pubmed.ncbi.nlm.nih.gov/42845185/
10. Expanding Access to Care: Implementation of a Pediatric and Young Adult Laser Hair Removal Program for Hidradenitis Suppurativa. - Pediatric dermatology, 2026 — PMID 42830514 · DOI 10.1111/pde.70373 - https://pubmed.ncbi.nlm.nih.gov/42830514/
11. Upcoming novel treatments for hidradenitis suppurativa: An overview of the pipeline. - Journal of the European Academy of Dermatology and Venereology : JEADV, 2026 — PMID 42828451 · DOI 10.1111/jdv.70749 - https://pubmed.ncbi.nlm.nih.gov/42828451/
12. Glucagon-like peptide-1 receptor agonists in hidradenitis suppurativa: A nationwide cohort study. - Journal of the European Academy of Dermatology and Venereology : JEADV, 2026 — PMID 42828450 · DOI 10.1111/jdv.70769 - https://pubmed.ncbi.nlm.nih.gov/42828450/
13. Infected von Meyenburg complex causing recurrent gram‑negative septicaemia: the critical diagnostic role of FDG‑PET/CT in a patient with hidradenitis suppurativa. - EJNMMI reports, 2026 — PMID 42825849 · DOI 10.1186/s41824-026-00324-5 · PMCID PMC13633229 - https://pubmed.ncbi.nlm.nih.gov/42825849/
14. Window of Opportunity and Predictors of Sustained Remission in Patients with Hidradenitis Suppurativa Treated with Adalimumab: A 540-Patient Cohort Study. - Dermatology and therapy, 2026 — PMID 42823605 · DOI 10.1007/s13555-026-01900-0 · PMCID PMC13650232 - https://pubmed.ncbi.nlm.nih.gov/42823605/
15. Sonelokimab, a novel IL-17A- and IL-17F-inhibiting nanobody for the treatment of moderate-to-severe hidradenitis suppurativa: a global, randomized, double-blind, placebo-controlled phase 2 clinical trial (MIRA). - Journal of the American Academy of Dermatology, 2026 — PMID 42822776 · DOI 10.1016/j.jaad.2026.09.099 - https://pubmed.ncbi.nlm.nih.gov/42822776/
16. The overlooked surface: cutaneous manifestations of inflammatory bowel disease. - Translational gastroenterology and hepatology, 2026 — PMID 42866820 · DOI 10.21037/tgh-2025-142 · PMCID PMC13657740 - https://pubmed.ncbi.nlm.nih.gov/42866820/
17. Immunoglobulin deposition and plasma cell infiltration define distinct immunopathological patterns in skin diseases. - Journal of dermatological science, 2026 — PMID 42875360 · DOI 10.1016/j.jdermsci.2026.08.011 - https://pubmed.ncbi.nlm.nih.gov/42875360/
18. Association between neighborhood disadvantage and surgical outcomes in hidradenitis suppurativa. - Burns : journal of the International Society for Burn Injuries, 2026 — PMID 42854440 · DOI 10.1016/j.burns.2026.108179 - https://pubmed.ncbi.nlm.nih.gov/42854440/
